BACKGROUND: Traumatic brain injury (TBI) is a worldwide cause of morbidity and mortality. Pentraxin 3 (PTX3) is a humoral component of the innate immune system which has been studied as a marker of inflammatory, infections or cardiovascular pathologies. To investigate the association between serum levels of PTX3 and the hospital mortality of patients with severe TBI. METHODS: The independent association between serum PTX3 levels after severe TBI (Glasgow Coma Scale, GCS ≤ 8) and hospital mortality was analyzed in a prospective study of 83 consecutive patients by a multiple logistic regression analysis. The leukocyte count in the same sample was analyzed as another marker of inflammatory response. RESULTS: The mean age of patients was 35 years and 85% were male. Serum PTX3 levels were determined 18.0 (SD ± 17.0) h after TBI. Patients who died showed a mean serum PTX3 level of 9.95 μg/ml (SD ± 6.42) in comparison to 5.46 μg/ml (SD ± 4.87) of the survivor group (P = 0.007). Elevated serum PTX3 levels remain significantly associated with mortality (P = 0.04) in the subset of patients with isolated TBI (n = 34). There were no differences in the leukocytes count measured in the same blood sample used for PTX3 determination in survivors and non-survivors (P = 0.56). The final multiple logistic regression model including age, pupillary examination, GCS, associated trauma, and PTX3 levels shows that serum levels of PTX3 which were higher than 10 μg/ml were independently associated with the patients mortality (adjusted OR 3.06, CI 95% 1.03-9.15, P = 0.04). CONCLUSIONS: Serum PTX3 levels after severe TBI are independently associated with higher hospital mortality and may be a useful marker of TBI and its prognosis.
BACKGROUND:Traumatic brain injury (TBI) is a worldwide cause of morbidity and mortality. Pentraxin 3 (PTX3) is a humoral component of the innate immune system which has been studied as a marker of inflammatory, infections or cardiovascular pathologies. To investigate the association between serum levels of PTX3 and the hospital mortality of patients with severe TBI. METHODS: The independent association between serum PTX3 levels after severe TBI (Glasgow Coma Scale, GCS ≤ 8) and hospital mortality was analyzed in a prospective study of 83 consecutive patients by a multiple logistic regression analysis. The leukocyte count in the same sample was analyzed as another marker of inflammatory response. RESULTS: The mean age of patients was 35 years and 85% were male. Serum PTX3 levels were determined 18.0 (SD ± 17.0) h after TBI. Patients who died showed a mean serum PTX3 level of 9.95 μg/ml (SD ± 6.42) in comparison to 5.46 μg/ml (SD ± 4.87) of the survivor group (P = 0.007). Elevated serum PTX3 levels remain significantly associated with mortality (P = 0.04) in the subset of patients with isolated TBI (n = 34). There were no differences in the leukocytes count measured in the same blood sample used for PTX3 determination in survivors and non-survivors (P = 0.56). The final multiple logistic regression model including age, pupillary examination, GCS, associated trauma, and PTX3 levels shows that serum levels of PTX3 which were higher than 10 μg/ml were independently associated with the patients mortality (adjusted OR 3.06, CI 95% 1.03-9.15, P = 0.04). CONCLUSIONS: Serum PTX3 levels after severe TBI are independently associated with higher hospital mortality and may be a useful marker of TBI and its prognosis.
Authors: T Ravizza; D Moneta; B Bottazzi; G Peri; C Garlanda; E Hirsch; G J Richards; A Mantovani; A Vezzani Journal: Neuroscience Date: 2001 Impact factor: 3.590
Authors: N Polentarutti; B Bottazzi; E Di Santo; E Blasi; D Agnello; P Ghezzi; M Introna; T Bartfai; G Richards; A Mantovani Journal: J Neuroimmunol Date: 2000-07-01 Impact factor: 3.478
Authors: Matti Vänskä; Irma Koivula; Sari Hämäläinen; Kari Pulkki; Tapio Nousiainen; Esa Jantunen; Auni Juutilainen Journal: Haematologica Date: 2011-09 Impact factor: 9.941
Authors: Patrick M Ketter; M Neal Guentzel; Beverly Schaffer; Maryanne Herzig; Xiaowu Wu; Robbie K Montgomery; Bijaya K Parida; Chriselda G Fedyk; Jieh-Juen Yu; James Jorgensen; James P Chambers; Andrew P Cap; Bernard P Arulanandam Journal: Infect Immun Date: 2014-07-07 Impact factor: 3.441
Authors: Imo P Aisiku; Jose-Miguel Yamal; Pratik Doshi; Julia S Benoit; Shankar Gopinath; Jerry C Goodman; Claudia S Robertson Journal: Crit Care Date: 2016-09-15 Impact factor: 9.097
Authors: Alexandre Hohl; Fernando Areas Zanela; Gabriela Ghisi; Marcelo Fernando Ronsoni; Alexandre Paim Diaz; Marcelo Liborio Schwarzbold; Alcir Luiz Dafre; Benjamin Reddi; Kátia Lin; Felipe Dal Pizzol; Roger Walz Journal: Front Endocrinol (Lausanne) Date: 2018-02-13 Impact factor: 5.555
Authors: David Tweedie; Hanuma Kumar Karnati; Roger Mullins; Chaim G Pick; Barry J Hoffer; Edward J Goetzl; Dimitrios Kapogiannis; Nigel H Greig Journal: Elife Date: 2020-08-17 Impact factor: 8.140